CLEAR Harmony OLE

NCT03067441

Principal Investigator: Dr. John Collins, MD (S. Washington Office)

Condition: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease

Drug: bempedoic acid

Official Title: Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Sponsor: Esperion Therapeutics

Purpose: The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

Inclusion Criteria:

• Successfully completed CLEAR Harmony (1002-040) parent study

Exclusion Criteria:

- Experienced a treatment-related SAE that led to study drug discontinuation in the CLEAR Harmony (1002-040) parent study.
- Medical condition requires lipid measurement and/or adjustment of background lipid-regulating therapy.

Source: https://clinicaltrials.gov/ct2/show/NCT03067441

Retrieved on: 7/7/2017